{"classes":[{"categories":[{"measurements":[{"comment":"The median could not be estimated due to the low number of events.","groupId":"OG000","lowerLimit":"33.97","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"113"}],"units":"Participants"}],"description":"OS was defined as the time from start of treatment (date of first intake of any study treatment component) to death from any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were enrolled in an induction phase and received 6-8 cycles of obinutuzumab, combined with 6 or 8 cycles of standard chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone/methylprednisolone \\[CHOP - 21-day cycle) or bendamustine (28-day cycle), or cyclophosphamide, vincristine, and prednisone/prednisolone/methylprednisolone \\[CVP - 21-day cycle\\]). Participants received an additional two doses of obinutuzumab on Days 8 and 15 of Cycle 1. The investigator was free to choose the chemotherapy for each participant.","id":"OG000","title":"All Participants"}],"paramType":"MEDIAN","populationDescription":"The safety population included all participants who received at least one dose of obinutuzumab.","reportingStatus":"POSTED","timeFrame":"Baseline up to end of study (up to approximately 4 years)","title":"Overall Survival (OS) at the End of the Study","type":"SECONDARY","unitOfMeasure":"Months"}